Tag - Myomo

Myomo Welcomes 13 New Center of Excellence Locations

Myomo, Inc., a commercial stage medical robotics company, today announced the addition of three new orthotics and prosthetics (O&P) practices and 13 new locations to its MyoPro Center of Excellence (CoE) program, which recognizes top O&P practices that support the MyoPro line of powered orthoses. The addition of the practices brings the total number of CoE locations across the United States to 46. Read more >>

Myomo Completes Repayment of Loan to the Massachusetts Life Sciences Center

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, and the Massachusetts Life Sciences Center (MLSC) today celebrated Myomo’s repayment of a $750,000 accelerator loan provided by the MLSC in 2011. Myomo completed repayment of the loan, which totaled $1,350,618 with interest, on December 13, 2017. Myomo Chairman and CEO Paul R. Gudonis presented a ceremonial check to Travis McCready, President and CEO of MLSC, during a ceremony at Myomo’s headquarters in the […]

Myomo to Present at Noble Capital Markets’ 14th Annual Investor Conference

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will be presenting at NobleCon14 – Noble Capital Markets’ Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Monday, January 29th at 11:00 AM EST – Studio 4. Chairman and Chief Executive Officer Paul R. Gudonis will be presenting, as well as meeting with investors. Read more >>

Myomo, Inc. Announces Full Exercise of Underwriter’s Over-Allotment Option in Follow-On Public Offering

Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that Roth Capital Partners, the underwriter of Myomo’s follow-on offering, exercised in full its option to purchase 626,250 shares of common stock and accompanying warrants to purchase 626,250 shares of common stock, at a combined price to the public of $2.40 per share of common stock and accompanying warrant, for gross proceeds of approximately $1.5 million. Read more >>

Just the Facts on Myomo, Inc. (MYO)

Myomo, Inc. (MYO) is an interesting player in the Healthcare space, with a focus on Medical Appliances & Equipment. The stock has been active on the tape, currently trading at $2.21, down from yesterday’s close by -24.04%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data. Read more >>

Myomo, Inc. Announces Pricing of Public Offering

Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that it has priced an underwritten public offering of 4,175,000 shares of its common stock and accompanying warrants to purchase 4,175,000 shares of common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock, at a combined price to the public of $2.40 per share of common stock and accompanying warrant, for gross proceeds of approximately […]

Myomo Expands MyoPro® Centers of Excellence Program

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced the addition of six new orthotics and prosthetics (O&P) locations to its Center of Excellence (CoE) program, which recognizes top O&P practices that support the MyoPro line of powered orthoses. MyoPro is currently the only lightweight wearable device that can help restore function in the paralyzed or weakened arms and hands of individuals who have suffered a stroke, brachial plexus injury (BPI) […]

Myomo, Inc. to Present at the 10th Annual LD Micro Main Event

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will be presenting at the 10th annual LD Micro Main Event on Tuesday, December 5th at 9:30 AM PST / 12:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Chairman and Chief Executive Officer Paul R. Gudonis will be presenting, as well as meeting with investors. Read more >>